Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23- valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients.

Similar presentations


Presentation on theme: "Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23- valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients."— Presentation transcript:

1 Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23- valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study  S.J. Vandecasteele, D. De Bacquer, R. Caluwe, S. Ombelet, B. Van Vlem  Clinical Microbiology and Infection  Volume 24, Issue 1, Pages (January 2018) DOI: /j.cmi Copyright © Terms and Conditions

2 Fig. 1 Study design and outcome (LOF, lost to follow up; transplant, kidney transplantation). Clinical Microbiology and Infection  , 65-71DOI: ( /j.cmi ) Copyright © Terms and Conditions


Download ppt "Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23- valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients."

Similar presentations


Ads by Google